In terms of the incidence among all tumors, skin cancer is on top, with the most deadly among them being melanoma. The search for new therapeutic agents to combat melanoma is very relevant. In our opinion, antisense oligonucleotides (ASO) aimed at suppressing the genes responsible for their viability in cancer cells give hope for treatment, which makes it possible to eliminate cancer cells near the tumor site both before and after surgery. In this article, we describe how Skeen-11 phosphorothioate oligonucleotide significantly decreased the proliferative activity of murine melanoma cells. Injections of Skeen-11 also inhibited tumor growth in mice with inoculated melanoma. A toxicity study showed no side effects with dose adjustments. The results show that the use of ASO Skeen-11 in vivo reduced the tumor size within 7 days, reduced the number of mitoses in the tumor cells, and increased the amount of necrosis compared with the control group.
Antisense technologies represent a promising approach in the development of therapeutic strategies for a wide range of diseases. Advances in the understanding of disease pathogenesis and molecular mechanisms underlying gastric mucosal injury, as well as the associated signaling pathways, have enabled the identification of multiple targets for phosphorothioate antisense oligonucleotides (ASOs). In this study, we evaluated cyclooxygenase-2 (COX-2) gene expression, histological and morphological changes in the gastric tissue of Wistar rats, as well as hematological parameters and systemic physiological indicators. Phosphorothioate ASOs exhibit high sequence specificity, binding to target mRNA and inducing its degradation, thereby reducing the expression of the corresponding protein. For the first time, we report an analysis of the effects of the phosphorothioate antisense oligonucleotide Regenera-11 and its modified variants (Regenera-5′ and Regenera-3′) in a prednisolone-induced gastric mucosal injury model in Wistar rats. Suppression of COX-2 expression was associated with enhanced mucosal repair and a reduction in the severity of histological damage. These findings suggest that Regenera-11 may represent a promising candidate for further preclinical investigation and the development of targeted therapeutic strategies.